Tetragon

Tetragon Therapeutics is a biotechnology company dedicated to developing novel small molecule therapeutics that target the Hippo signaling pathway. The company focuses on disrupting the YAP/TEAD transcriptional complex, a key driver in the progression of various aggressive cancers and fibrotic diseases. By leveraging deep structural biology insights and the expertise of its founding scientists, Tetragon is advancing a pipeline of potent inhibitors designed to treat Hippo-driven malignancies such as mesothelioma and NF2-deficient tumors. Their approach aims to provide precision medicine options for patients with limited therapeutic alternatives. The company operates with a global footprint, maintaining research and development activities in both Singapore and the United States.